Int. J. Mol. Sci. 2011, 12(9), 5895-5907; doi:10.3390/ijms12095895
Review

Looking to the Future: Biomarkers in the Management of Pancreatic Adenocarcinoma

Received: 5 August 2011; in revised form: 30 August 2011 / Accepted: 8 September 2011 / Published: 14 September 2011
(This article belongs to the Special Issue Biomarkers 2011)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: The incidence and mortality of pancreas cancer converge. There has been little advancement in the treatment of pancreas cancer since the acceptance of gemcitabine as the standard therapy. Unfortunately, the efficacy of gemcitabine is dismal. While there is much discussion for the development of biomarkers to help direct therapy in this area, there is little action to move them into clinical practice. Herein, we review potential pancreatic cancer biomarkers and discuss the limitations in their implementation.
Keywords: pancreatic adenocarcinoma; hENT1; hCNT3; SPARC; cDK; biomarker; clinical trials; gemcitabine; oxaliplatin
PDF Full-text Download PDF Full-Text [182 KB, uploaded 19 June 2014 03:58 CEST]

Export to BibTeX |
EndNote


MDPI and ACS Style

Spratlin, J.L.; Mulder, K.E. Looking to the Future: Biomarkers in the Management of Pancreatic Adenocarcinoma. Int. J. Mol. Sci. 2011, 12, 5895-5907.

AMA Style

Spratlin JL, Mulder KE. Looking to the Future: Biomarkers in the Management of Pancreatic Adenocarcinoma. International Journal of Molecular Sciences. 2011; 12(9):5895-5907.

Chicago/Turabian Style

Spratlin, Jennifer L.; Mulder, Karen E. 2011. "Looking to the Future: Biomarkers in the Management of Pancreatic Adenocarcinoma." Int. J. Mol. Sci. 12, no. 9: 5895-5907.

Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert